Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Molecular Partners AG - American Depositary Shares (MOLN)
Company Research
Source: Yahoo! Finance
Radio-DARPin Therapy (RDT): Lead DLL3 candidate advancing into IND-enabling studies with partner Orano Med, preclinical data to be presented at SNMMI 2024 Switch-DARPin Platform: Initial data to be presented at EHA 2024; Preclinical proof-of-concept studies for c-KIT program planned for H2 2024 MP0317: Final data from Phase 1 dose escalation to be presented at ASCO 2024 Outlook: Funded into 2026 with cash and short-term deposits of CHF 174.1 million; total operating expenses of CHF 70-80 million expected for 2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges that other drug modalities cannot readily address ("Molecular Partners" or the "Company"), today announced corporate highlights and unaudited financial results for the first quart
Show less
Read more
Impact Snapshot
Event Time:
MOLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MOLN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MOLN alerts
High impacting Molecular Partners AG - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
MOLN
News
- Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation SummitGlobeNewswire
- Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024 [Yahoo! Finance]Yahoo! Finance
- Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024GlobeNewswire
- Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024 [Yahoo! Finance]Yahoo! Finance
- Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024GlobeNewswire
MOLN
Sec Filings
- 6/14/24 - Form 6-K
- 6/11/24 - Form 6-K
- 6/3/24 - Form 6-K
- MOLN's page on the SEC website